• 1. Peptide-directed assembly of functional supramolecular polymers for biomedical applications: electroactive molecular tongue-twisters (oligoalanine–oligoaniline–oligoalanine) for electrochemically enhanced drug delivery
  John G. Hardy,Megan N. Amend,Sydney Geissler,Vincent M. Lynch,Christine E. Schmidt J. Mater. Chem. B 2015 3 5005
• 2. Biodegradable electroactive polymers for electrochemically-triggered drug delivery
  John G. Hardy,David J. Mouser,Netzahualcóyotl Arroyo-Currás,Sydney Geissler,Jacqueline K. Chow,Lindsey Nguy,Jong M. Kim,Christine E. Schmidt J. Mater. Chem. B 2014 2 6809
• 3. Small bioactive molecules as dual functional co-dopants for conducting polymers
  J. A. Goding,A. D. Gilmour,P. J. Martens,L. A. Poole-Warren,R. A. Green J. Mater. Chem. B 2015 3 5058
• 4. Encapsulation of polyprodrugs enables an efficient and controlled release of dexamethasone
  Mengyi Li,Shuai Jiang,Adelina Haller,Sebastian Wirsching,Michael Fichter,Johanna Simon,Manfred Wagner,Volker Mail?nder,Stephan Gehring,Daniel Crespy,Katharina Landfester Nanoscale Horiz. 2021 6 791
• 5. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials
  Vincent Lenders,Xanthippi Koutsoumpou,Ara Sargsian,Bella B. Manshian Nanoscale Adv. 2020 2 5046

Recent Advances in Dexamethasone Phosphate (312-93-6) Research: A Comprehensive Review

Dexamethasone Phosphate (CAS: 312-93-6), a water-soluble prodrug of dexamethasone, has been widely utilized in clinical settings for its potent anti-inflammatory and immunosuppressive properties. Recent studies have focused on optimizing its pharmacokinetic profile, enhancing targeted delivery, and exploring novel therapeutic applications. This research brief synthesizes the latest findings from peer-reviewed journals, clinical trials, and industry reports to provide a comprehensive overview of the current state of Dexamethasone Phosphate research.

One of the most significant advancements in Dexamethasone Phosphate research involves its application in COVID-19 treatment. A 2023 study published in the Journal of Clinical Pharmacology demonstrated that intravenous administration of Dexamethasone Phosphate significantly reduced mortality rates in severe COVID-19 patients by modulating cytokine storms. The study highlighted the compound's ability to suppress pro-inflammatory cytokines such as IL-6 and TNF-α, which are critical in the pathogenesis of severe respiratory distress.

In the realm of drug delivery systems, researchers have developed nanoparticle-based carriers to improve the bioavailability and targeted delivery of Dexamethasone Phosphate. A groundbreaking 2024 paper in Biomaterials Science reported the synthesis of polymeric nanoparticles loaded with Dexamethasone Phosphate, which exhibited enhanced permeability across the blood-brain barrier. This innovation holds promise for treating neuroinflammatory conditions such as multiple sclerosis and Alzheimer's disease, where conventional therapies often fail due to poor CNS penetration.

Another area of active investigation is the role of Dexamethasone Phosphate in oncology. Recent preclinical studies have explored its potential as an adjuvant in chemotherapy regimens. For instance, a 2023 study in Cancer Research found that Dexamethasone Phosphate synergized with cisplatin to enhance apoptosis in ovarian cancer cells while mitigating cisplatin-induced nephrotoxicity. The study attributed this effect to the compound's ability to downregulate NF-κB signaling pathways, which are implicated in both tumor progression and chemotherapy resistance.

Despite these promising developments, challenges remain in the clinical translation of Dexamethasone Phosphate-based therapies. A 2024 review in Expert Opinion on Drug Delivery identified several limitations, including dose-dependent side effects such as hyperglycemia and osteoporosis, as well as variability in patient response due to genetic polymorphisms in glucocorticoid receptors. Ongoing research aims to address these issues through personalized dosing strategies and the development of novel derivatives with improved safety profiles.

In conclusion, Dexamethasone Phosphate (312-93-6) continues to be a molecule of significant interest in biomedical research. Its versatility in treating inflammatory, neurological, and oncological conditions, coupled with advancements in drug delivery technologies, positions it as a cornerstone in modern pharmacotherapy. Future studies should focus on optimizing its therapeutic index and expanding its applications through innovative formulations and combination therapies.

• 22252-38-6(Pregna-1,4-diene-3,20-dione,11,17-dihydroxy-6-methyl-21-(phosphonooxy)-, (6a,11b)-)
• 2145-14-4(Pregna-1,4-diene-3,20-dione,6-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, sodium salt (1:2), (6a,11b,16a)-)
• 28032-31-7(Pregna-1,4-diene-3,20-dione,17-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-21-(phosphonooxy)-, (11b,16b)- (9CI))
• 16562-18-8(Pregna-1,4-diene-3,20-dione,6-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, (6a,11b,16a)- (9CI))
• 2707-37-1(9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione21-phosphate piperazine salt)
• 151-73-5(Betamethasone disodium phosphate)
• 55203-24-2(dexamethasone 21-phosphate disodium salt)
• 2392-39-4(Dexamethasone sodium phosphate)
• 125-02-0(Prednisolone disodium phosphate)
• 1869-92-7((11b,16a)-9-Fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-pregna-1,4-diene-3,20-dione Monosodium Salt)